PD-1 Blockade Falls Short (Repeatedly) in Prostate Cancer

被引：3
|
作者：
Dolgin, Elie
机构：
来源：
CANCER DISCOVERY | 2023年 / 13卷 / 05期
关键词：
D O I：
10.1158/2159-8290.CD-NB2023-0017
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Late-stage trials evaluating the PD-1 inhibitor pembrolizumab in men with prostate cancer have all ended in failure, leading clinicians to conclude that new treatment strategies are needed to help make checkpoint blockade more effective in the immune-suppressed environment of most prostate tumors. ©2023 American Association for Cancer Research.
引用
收藏
页码：1032 / 1033
页数：5
相关论文
共 50 条
  • [1] Cancer immunotherapy by PD-1 blockade
    Honjo, Tasuku
    CANCER SCIENCE, 2018, 109 : 197 - 197
  • [2] PD-1 blockade therapy for cancer
    Ribas, Antoni
    CANCER IMMUNOLOGY RESEARCH, 2015, 3 (10)
  • [3] PD-1 BLOCKADE IN CANCER IMMUNOTHERAPY
    Srivastava, N.
    Avigan, D.
    Rosenblatt, J.
    DRUGS OF THE FUTURE, 2014, 39 (02) : 129 - 132
  • [4] PD-1 blockade in nonmelanoma skin cancer
    Winkler, J. K.
    Bender, C.
    Enk, A.
    Hassel, J. C.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 150 - 150
  • [5] Application of PD-1 Blockade in Cancer Immunotherapy
    Wu, Xiaomo
    Gu, Zhongkai
    Chen, Yang
    Chen, Borui
    Chen, Wei
    Weng, Liqiang
    Liu, Xiaolong
    COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL, 2019, 17 : 661 - 674
  • [6] PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer?
    Tanvetyanon, Tawee
    Gray, Jhanelle E.
    Antonia, Scott J.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2017, 17 (03) : 305 - 312
  • [7] Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
    Forde, P. M.
    Chaft, J. E.
    Smith, K. N.
    Anagnostou, V.
    Cottrell, T. R.
    Hellmann, M. D.
    Zahurak, M.
    Yang, S. C.
    Jones, D. R.
    Broderick, S.
    Battafarano, R. J.
    Velez, M. J.
    Rekhtman, N.
    Olah, Z.
    Naidoo, J.
    Marrone, K. A.
    Verde, F.
    Guo, H.
    Zhang, J.
    Caushi, J. X.
    Chan, H. Y.
    Sidhom, J. -W.
    Scharpf, R. B.
    White, J.
    Gabrielson, E.
    Wang, H.
    Rosner, G. L.
    Rusch, V.
    Wolchok, J. D.
    Merghoub, T.
    Taube, J. M.
    Velculescu, V. E.
    Topalian, S. L.
    Brahmer, J. R.
    Pardoll, D. M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (21): : 1976 - 1986
  • [8] PD-1 Blockade Cellular Vesicles for Cancer Immunotherapy
    Zhang, Xudong
    Wang, Chao
    Wang, Jinqiang
    Hu, Quanyin
    Langworthy, Benjamin
    Ye, Yanqi
    Sun, Wujin
    Lin, Jing
    Wang, Tianfu
    Fine, Jason
    Cheng, Hao
    Dotti, Gianpietro
    Huang, Peng
    Gu, Zhen
    ADVANCED MATERIALS, 2018, 30 (22)
  • [9] Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
    Yang, Xin
    Yin, Rong
    Xu, Lin
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (09):
  • [10] Neoadjuvant PD-1 blockade in resectable lung cancer
    Forde, Patrick M.
    Chaft, Jamie E.
    Smith, Kellie N.
    Anagnostou, Valsamo
    Cottrell, Tricia R.
    Hellmann, Matthew D.
    Zahurak, Marianna
    Yang, Stephen C.
    Jones, David R.
    Broderick, Stephen
    Battafarano, Richard J.
    Velez, Moises J.
    Rekhtman, Natasha
    Olah, Zachary
    Naidoo, Jarushka
    Marrone, Kristen A.
    Verde, Franco
    Guo, Haidan
    Zhang, Jiajia
    Caushi, Justina X.
    Chan, Hok Yee
    Sidhom, John-William
    Scharpf, Robert B.
    White, James
    Gabrielson, Edward
    Wang, Hao
    Rosner, Gary L.
    Rusch, Valerie
    Wolchok, Jedd D.
    Merghoub, Taha
    Taube, Janis M.
    Velculescu, Victor E.
    Topalian, Suzanne L.
    Brahmer, Julie R.
    Pardoll, Drew M.
    CANCER RESEARCH, 2018, 78 (13)
12345